Role of vasopressin during hysteroscopic surgery for fibroid.
Phase 4
- Conditions
- Health Condition 1: N858- Other specified noninflammatory disorders of uterus
- Registration Number
- CTRI/2020/09/027811
- Lead Sponsor
- Dr SMurali
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Type0 ,1 and 2 myoma (Submucous myoma) who are scheduled to undergo hysteroscopic myomectomy
Exclusion Criteria
1. Myoma > 5cm size
2. Acute PID
3. Use of preoperative GnRH agonists
4. Endometrial premalignant or malignant pathologies
5. Women with cardiopulmonary diseases, bleeding diathesis and renal disease.
6. Patients with multiple submucous myoma.
7. Hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the operative time between patients in whom intralesional vasopressin has been administered and patients in whom it was not administered during hysteroscopic myomectomy.Timepoint: Beginning of surgery to end of surgery. Time point is immediately after surgery.
- Secondary Outcome Measures
Name Time Method To compare blood loss, fluid overload, visual clarity and complications in between patients in whom intralesional vasopressin has been administered and patients in whom it was not administered during hysteroscopic myomectomy.Timepoint: From beginning of surgery till end of surgery and at 2 weeks (for complications)